The Technical Analyst
Select Language :
Fusion Pharmaceuticals [FUSN]

Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology

Fusion Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Fusion Pharmaceuticals is listed at the NASDAQ Exchange

1.61% $2.53

Last updated: 3 jul 2022 - 20:31

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 109.66 mill
EPS: -1.943
P/E: 0.000
Earnings Date: Aug 08, 2022
SharesOutstanding: 43.34 mill
Avg Daily Volume: 0.0188 mill
RATING 2022-07-01
B+
Buy
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/201/212/213/214/211/22
Revenuen/an/an/an/an/a
Gr.Profitn/an/an/an/an/an/a
Ebit
Asset
Debtn/an/a
DISCOUNTED CASH FLOW VALUE
$3.76
(48.60%) $1.230
Date: 2022-07-04
True Range Average
+/- $0.240
( +/- 9.49%)
Range: 2.29 - 2.77
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-06-14 Preston Heather Buy 17 000 Stock Option (Right to Buy)
2022-06-14 Lee Philina Buy 17 000 Stock Option (Right to Buy)
2022-06-14 Khuong Chau Quang Buy 17 000 Stock Option (Right to Buy)
2022-06-14 Duncan Barbara Gayle Buy 17 000 Stock Opion (Right to Buy)
2022-06-14 Gannon Steven Buy 17 000 Stock Option (Right to Buy)
INSIDER POWER
55.13
Last 100 transactions
Buy: 9 940 507 | Sell: 13 555 489

Forecast: 16:00 - $2.53

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $2.53
Forecast 2: 16:00 - $2.53
Forecast 3: 16:00 - $2.53
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.53 (1.61% )
Volume 0.0034 mill
Avg. Vol. 0.0188 mill
% of Avg. Vol 18.05 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Fusion Pharmaceuticals Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Fusion Pharmaceuticals Inc.

RSI

Intraday RSI14 chart for Fusion Pharmaceuticals Inc.
The Live Chart for Fusion Pharmaceuticals Inc.
Profile picture for
            Fusion Pharmaceuticals Inc.

FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

Last 10 Buy Signals
Date Signal @
GNOUSDJul 3 - 20:29111.10
DCRUSDJul 3 - 20:2922.59
USDTUSDJul 3 - 20:290.999
UBQUSDJul 3 - 20:280.0337
LSKUSDJul 3 - 20:271.032
PIVXUSDJul 3 - 20:240.109
PARTUSDJul 3 - 20:240.328
QRLUSDJul 3 - 20:220.177
NXTUSDJul 3 - 20:220.0034
UBQUSDJul 3 - 20:220.0337

Stock Peers

Company Price Change
FUSN2.531.61%
ALDX3.80-4.76%
CBAY2.77-6.10%
CNCE4.271.43%
MYNZ9.401.08%
PROF7.492.74%
PROG0.885-3.47%
RYTM4.303.61%
TALK1.7402.35%
XAIR7.4210.91%
XBIT5.640.18%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.